Discrepancies between subjective and objective cognition in persons with multiple sclerosis: Exploring the role of cannabis use.

Discrepancies between subjective and objective cognition in persons with multiple sclerosis: Exploring the role of cannabis use.

CED Clinical Relevance  #72Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely.
🔬 Evidence Watch  |  CED Clinic
Multiple SclerosisCognitionPatient Reported OutcomesCannabis EffectsNeuropsychology
Journal Multiple sclerosis and related disorders
Study Type Clinical Study
Population Human participants
Why This Matters

This study addresses a critical clinical challenge: patients with multiple sclerosis using cannabis may overestimate their cognitive impairment relative to objective testing. Understanding this perceptual disconnect helps clinicians interpret patient-reported cognitive symptoms more accurately when cannabis is involved.

Clinical Summary

This cross-sectional study of 847 multiple sclerosis patients (254 cannabis users, 593 non-users) examined relationships between cannabis use and both subjective cognitive complaints and objective cognitive performance. Cannabis users reported significantly greater perceived cognitive deficits compared to non-users, while controlling for anxiety, depression, fatigue, and premorbid IQ. The study found discrepancies between self-reported cognitive problems and actual measured cognitive abilities, with cannabis users showing greater subjective impairment than their objective testing would suggest. This suggests cannabis use in MS patients may influence metacognitive awareness or symptom attribution patterns.

Dr. Caplan’s Take

“This finding doesn’t surprise me clinically – I’ve observed that cannabis-using MS patients often report cognitive concerns that don’t always align with their functional presentations. The mechanism behind this perceptual disconnect remains unclear and warrants careful clinical evaluation rather than dismissal of patient concerns.”

Clinical Perspective
🧠 Clinicians should interpret subjective cognitive complaints from cannabis-using MS patients with additional context, potentially incorporating objective cognitive assessments when feasible. Patient education about potential perceptual effects of cannabis on cognitive self-assessment may be valuable, while ensuring legitimate cognitive concerns aren’t dismissed.

💬 Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →

FAQ

Does cannabis use affect cognitive function in multiple sclerosis patients?

Yes, this study found that cannabis users with MS reported greater perceived cognitive deficits compared to non-users. Previous research has also shown detrimental effects of cannabis use on objective measures of cognitive performance in the MS population.

Are MS patients who use cannabis aware of their cognitive impairments?

The study revealed discrepancies between subjective and objective cognition, suggesting that cannabis users may have altered self-awareness of their cognitive abilities. This indicates that patients’ self-reported cognitive functioning may not accurately reflect their actual cognitive performance.

Should I advise my MS patients to avoid cannabis for cognitive reasons?

Based on this evidence showing increased perceived cognitive deficits and known objective cognitive impairments, clinicians should discuss potential cognitive risks with MS patients considering cannabis use. Patient counseling should include both the subjective experience of cognitive problems and documented objective performance deficits.

How should I assess cognitive function in MS patients who use cannabis?

Given the discrepancies between self-reported and objective cognitive functioning, clinicians should use both subjective cognitive assessments and objective neuropsychological testing. Self-report alone may not provide an accurate picture of cognitive abilities in cannabis-using MS patients.

What factors should be considered when evaluating cognitive complaints in MS patients?

The study controlled for anxiety, depression, fatigue, and premorbid IQ as important covariates affecting cognitive function. These factors, along with cannabis use status, should all be considered when evaluating and managing cognitive complaints in MS patients.






{“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Discrepancies between subjective and objective cognition in persons with multiple sclerosis: Exploring the role of cannabis use.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41313862/”, “about”: “multiple sclerosis related disorders clinical study”, “isPartOf”: “Multiple sclerosis and related disorders”}